Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its news flow reflects the progress of these programs. Company announcements highlight clinical data from trials of rondecabtagene autoleucel (ronde‑cel, also referred to as LYL314) in relapsed and/or refractory large B-cell lymphoma (LBCL), including reported overall response rates, complete response rates, durability of responses, and safety findings from Phase 1/2 and pivotal studies.
News updates frequently cover milestones in Lyell’s pivotal development of ronde‑cel, such as the initiation and conduct of the single‑arm PiNACLE trial in the third‑ or later‑line setting and the Phase 3 PiNACLE – H2H head‑to‑head trial in the second‑line setting against approved CD19 CAR T-cell therapies. These releases often include details on trial design, patient populations, endpoints, and presentations at major scientific meetings like the American Society of Hematology (ASH) and the International Conference on Malignant Lymphoma.
For solid tumors, Lyell’s news also reports on LYL273, a GCC‑targeted CAR T-cell product candidate in Phase 1 development for refractory metastatic colorectal cancer. Disclosures include response rates, disease control rates, safety observations, and regulatory designations such as Fast Track status from the U.S. FDA. Additional corporate news items describe licensing transactions, equity financings, and operational updates that support the advancement of Lyell’s pipeline and manufacturing capabilities.
Investors and observers following LYEL news can use this page to review company-issued press releases on clinical trial readouts, regulatory designations, scientific conference presentations, licensing agreements, and capital raises related to Lyell’s CAR T-cell programs in hematologic malignancies and solid tumors.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported financial results for Q4 and full year 2022, highlighting a net loss of $8.4 million for Q4 and $183.1 million for the year, but significantly increased revenue of $48.4 million for Q4 and $84.7 million for the year, up from $2.8 million and $10.7 million in 2021. The company's cash position stands at $710.3 million as of December 31, 2022, supporting ongoing clinical trials and a robust pipeline. Lyell initiated Phase 1 trials for two product candidates targeting solid tumors and presented promising nonclinical data at several conferences. The company expects initial clinical data from LYL797 and LYL845 in 2024.
Lyell Immunopharma will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 pm PT. The presentation will showcase Lyell's pipeline, including CAR T cell product candidates LYL797 and LYL845, both in Phase 1 trials, and the innovative LYL119 targeting ROR1. Key technologies will be highlighted, such as NR4A3 gene knockout and Stim-RTM for enhanced CAR T cell activity. A live webcast will be available on the company’s website with a 30-day replay.
Lyell Immunopharma (Nasdaq: LYEL) has appointed Lynn Seely, MD, as president & CEO, succeeding Liz Homans, who transitions to a consulting role until June 2024. Dr. Seely brings extensive biopharmaceutical leadership experience, having previously served as CEO of Myovant Sciences, where she successfully launched therapies for cancer and women's health. Under her leadership, Lyell aims to advance its clinical-stage programs and enhance its T-cell reprogramming technologies to improve treatment outcomes for solid tumors.
Lyell Immunopharma (Nasdaq: LYEL) is set to participate in the BofA Securities 2022 Biotech SMID Cap Conference on December 8, 2022, at 1:40 pm ET. The event will feature members of its senior management team, and a live webcast will be available on the company's website. This opportunity highlights Lyell's commitment to developing curative cell therapies for solid tumors, leveraging proprietary technologies to overcome key barriers in adoptive T-cell therapy. A replay of the webcast will be accessible for 90 days post-event.
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, announced participation in the Barclays Virtual Fireside Chat Series on November 17 at 11 a.m. ET. The event will feature senior management discussing advancements in curative cell therapies for solid tumors. A webcast of the presentation can be accessed on the company's investor relations website, with a replay available for 90 days afterwards. Lyell focuses on overcoming challenges in adoptive T-cell therapy through innovative genetic and epigenetic reprogramming technologies.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced FDA clearance of the IND for LYL845, advancing its TIL product candidate into clinical development. As of September 30, 2022, the company reported cash equivalents of $750.7 million, extending its financial runway into 2026. Revenue dipped to approximately zero in Q3 2022, down from $2.8 million in Q3 2021, reflecting no R&D under the GSK Agreement. The net loss increased to $70.3 million compared to $48.9 million year-over-year. Lyell is expected to present initial data for LYL845 in 2024.
Lyell Immunopharma (Nasdaq: LYEL) is presenting preclinical research at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing advancements in T-cell therapies targeting solid tumors. Key highlights include:
- LYL845 exhibits a 100% expansion success rate using Epi-R technology.
- Research indicates LYL845 maintains T-cell polyclonality and stem-like properties, enhancing anti-tumor efficacy.
- Innovative stackable reprogramming technologies are being developed for LYL119 to improve CAR T-cell therapies.
These findings aim to address T-cell exhaustion and enhance treatment outcomes in cancer patients.
Lyell Immunopharma (Nasdaq: LYEL) announced that its senior management will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 2:00 p.m. ET. The presentation will focus on the company’s innovative T-cell reprogramming technologies aimed at developing curative cell therapies for solid tumors. A live webcast will be available on the company's investor relations website, with a replay accessible for 90 days after the event.
Lyell Immunopharma has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845, a tumor infiltrating lymphocyte (TIL) therapy utilizing Lyell’s proprietary Epi-R technology. This trial will focus on patients with relapsed or refractory melanoma, expanding later to include non-small cell lung cancer and colorectal cancer. Initial data presentation is anticipated in 2024. This marks Lyell's second product candidate to receive IND clearance within the last year, showcasing progress in its mission to develop curative T-cell therapies.
Lyell Immunopharma (LYEL) announced its participation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) with five accepted abstracts highlighting new preclinical data. This data focuses on T-cell reprogramming technologies incorporated in LYL119, an investigational ROR1 targeting CAR T-cell therapy. The findings aim to enhance T cell functionality and combat exhaustion in solid tumors, showcasing Lyell's efforts in advancing its therapeutic pipeline to improve patient outcomes in adoptive cell therapy.